Abstract
The multidrug resistance (MDR) of tumor cells significantly reduces the efficiency of traditional anticancer therapy. Tumor MDR is complex and involves several mechanisms such as decreased drug uptake, increased drug efflux, enhanced drug exocytosis, increased drug detoxification and inactivation by drugmetabolizing enzymes, altered drug targets due to genetic and epigenetic modifications, altered DNA repair, and impaired apoptotic pathways. Implementation of nanoparticles can markedly improve drug delivery through increased stability in the plasma, prolonged half-life, enhanced specificity of transfer, and advanced drug accumulation and retention in the tumor cells. So far, many various types of nanocarriers have been used for the delivery of anticancer agents. These carriers greatly increase anti-tumor effects of cytotoxic agents since drug-carrying nanoparticles are able to reverse MDR. The promising integrative approach in cancer nanotherapy assumes the development of multifunctional delivery systems simultaneously transmitting various agents such as drugs, genes, imaging agents, and targeting ligands in order to enhance anti-tumor toxicity and nanoparticle tracking.
Keywords: Multidrug resistance, cancer chemotherapy, nanoparticles, drug delivery, cytotoxicity, tumor.
Current Pharmaceutical Design
Title:Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives
Volume: 23 Issue: 22
Author(s): Dimitry A. Chistiakov, Veronika A. Myasoedova, Alexander N. Orekhov and Yuri V. Bobryshev*
Affiliation:
- Institute for Atherosclerosis Research, Skolkovo Innovative Center, Moscow 121609,Russian Federation
Keywords: Multidrug resistance, cancer chemotherapy, nanoparticles, drug delivery, cytotoxicity, tumor.
Abstract: The multidrug resistance (MDR) of tumor cells significantly reduces the efficiency of traditional anticancer therapy. Tumor MDR is complex and involves several mechanisms such as decreased drug uptake, increased drug efflux, enhanced drug exocytosis, increased drug detoxification and inactivation by drugmetabolizing enzymes, altered drug targets due to genetic and epigenetic modifications, altered DNA repair, and impaired apoptotic pathways. Implementation of nanoparticles can markedly improve drug delivery through increased stability in the plasma, prolonged half-life, enhanced specificity of transfer, and advanced drug accumulation and retention in the tumor cells. So far, many various types of nanocarriers have been used for the delivery of anticancer agents. These carriers greatly increase anti-tumor effects of cytotoxic agents since drug-carrying nanoparticles are able to reverse MDR. The promising integrative approach in cancer nanotherapy assumes the development of multifunctional delivery systems simultaneously transmitting various agents such as drugs, genes, imaging agents, and targeting ligands in order to enhance anti-tumor toxicity and nanoparticle tracking.
Export Options
About this article
Cite this article as:
Chistiakov A. Dimitry, Myasoedova A. Veronika , Orekhov N. Alexander and Bobryshev V. Yuri *, Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives, Current Pharmaceutical Design 2017; 23 (22) . https://dx.doi.org/10.2174/1381612823666170407123941
DOI https://dx.doi.org/10.2174/1381612823666170407123941 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insulin Resistance, Glycemic Control and Adiposity: Key Determinants of Healthy Lifespan
Current Alzheimer Research Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design Glucose Sensors Based on Core@Shell Magnetic Nanomaterials and Their Application in Diabetes Management: A Review
Current Pharmaceutical Design Dietary Carbohydrates that Modulate the Immune System
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets Design and Synthesis of New N1 and C3-Substituted 4-Fluoroindolic Melatoninergics
Current Drug Discovery Technologies Aromatase Inhibitors: A New Paradigm in Breast Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Application of Non-flavonoid Phenolics in Diabetes: Antiinflammatory Effects
Current Medicinal Chemistry Role of the Cytoskeleton in Steroidogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Linkage “Body Mass Index-Insomnia Levels-Eating Disorder Flexibility” in Italian Nurses During the Covid-19 Outbreak: A Psychoendocrinological Employment Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Probiotics for the Prevention and Treatment of Allergies, with an Emphasis on Mode of Delivery and Mechanism of Action
Current Pharmaceutical Design Radiolabelled Regulatory Peptides for Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry CYP17 Inhibitors for Prostate Cancer Treatment – An Update
Current Medicinal Chemistry Subject Index to Volume 10
Current Medicinal Chemistry The Role of PPARβ/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Insight into the Mechanism of 17β-Hydroxysteroid Dehydrogenase Type 3 Inhibition by the Androsterone Derivative RM-532-105
Current Enzyme Inhibition Meet Our Editorial Board Member
Endocrine, Metabolic & Immune Disorders - Drug Targets Stem Cell Research and Therapy for Liver Disease
Current Stem Cell Research & Therapy NF-κB Signature on the Aging Wall
Current Drug Metabolism